Astrazeneca
astrazeneca.ru
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
News
Alnylam defends heart disease drugs after failure of AstraZeneca's Wainua
As the debate of silencers versus stabilizers continues in ATTR-CM, Alnylam is mounting a defense of its medicines.
Read more
Report
AstraZeneca, Amgen poised to challenge Dupixent's reign with esophagitis win
Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen's Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
Read more
Report
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
The surprise failure of the drug from AstraZeneca and Ionis took a competitor out of the hotly contested ATTR-CM market.
Read more
Report
AstraZeneca, Ionis data spark debate about RNA drugs' impact on deadly heart disease
Results published in NEJM raised questions about the benefits
Read more
Report
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion into chronic rhinosinusitis last year.
Read more
Report
Pro access
Upgrade to see all 38 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.